Biotech · Public company · Sugar Land, TX, US
Tvardi Therapeutics, Inc.
Ticker TVRD · SEC CIK 0001346830
Track this companyFree. Adds Tvardi Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline10
- AtezolizumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TTI-101Phase 2 · Idiopathic Pulmonary FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- TTI-101Phase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Aromatase inhibitor (AI)Phase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- fulvestrantPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PalbociclibPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ribociclibPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- TTI-101Phase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal AdenocarcinomaPHASE1 · RECRUITING · started Jan 16, 2024ClinicalTrials.gov NCT06141031 · fetched Nov 12, 2026
- Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisPHASE2 · COMPLETED · started May 15, 2023ClinicalTrials.gov NCT05671835 · fetched Nov 12, 2026
- A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaPHASE1_PHASE2 · RECRUITING · started Mar 23, 2023ClinicalTrials.gov NCT05440708 · fetched Nov 12, 2026
- Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerPHASE1 · TERMINATED · started Jan 9, 2023ClinicalTrials.gov NCT05384119 · fetched Nov 12, 2026
- Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced CancersPHASE1 · COMPLETED · started Nov 15, 2017ClinicalTrials.gov NCT03195699 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 17, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 7, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jan 16, 2026 · fetched Nov 12, 2026